Abstract
One hundred and forty-four patients with advanced renal cell cancer were evaluated for objective response to single-agent treatment with megestrol acetate, VP-16-213, cyclophosphamide, or dianhydrogalactitol. In view of the low order of response observed, these agents do not appear to be effective in the treatment of metastatic renal cell cancer. Performance status and a relatively long interval from onset of primary symptoms to study entry were the most favorable prognostic variables affecting time to progression and survival for patients in this study.
Publication types
-
Clinical Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adult
-
Aged
-
Clinical Trials as Topic
-
Cyclophosphamide / adverse effects
-
Cyclophosphamide / therapeutic use*
-
Dianhydrogalactitol / adverse effects
-
Dianhydrogalactitol / therapeutic use*
-
Drug Evaluation
-
Etoposide / therapeutic use*
-
Humans
-
Kidney Neoplasms / drug therapy*
-
Megestrol / therapeutic use*
-
Middle Aged
-
Neoplasm Metastasis
-
Podophyllotoxin / analogs & derivatives*
-
Sugar Alcohols / therapeutic use*
Substances
-
Sugar Alcohols
-
Dianhydrogalactitol
-
Etoposide
-
Cyclophosphamide
-
Megestrol
-
Podophyllotoxin